1194 CHARACTERIZATION OF VIRAL ESCAPE IN HCV GENOTYPE 1-INFECTED PATIENTS TREATED WITH BMS-791325 AND PEGYLATED INTERFERON-ALFA AND RIBAVIRIN

1193 A DESCRIPTION OF VIROLOGIC ESCAPE IN HCV GENOTYPE 1-INFECTED PATIENTS TREATED WITH DACLATASVIR (BMS-790052) IN COMBINATION WITH RIBAVIRIN AND PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B F. McPhee, D. Hernandez, F. Yu, J. Ueland, K. Chayama, J. Toyota, N. Izumi, O. Yokosuka, N. Kawada, Y. Osaki, E. Hughes, H. Watanabe, H. Ishikawa, H. Kumada. Clinical Research and Development, Bristol-Myers Squibb, Wallingford, CT, USA; Hiroshima University, Hiroshima, Sapporo-Kousei General Hospital, Sapporo, Musashino Red Cross Hospital, Tokyo, Chiba University, Chiba, Osaka City University, Osaka Red Cross Hospital, Osaka, Japan; Research and Development, Bristol-Myers Squibb, Princeton, NJ, USA; Bristol-Myers KK, Toranomon Hospital, Tokyo, Japan E-mail: fiona.mcphee@bms.com